<DOC>
	<DOCNO>NCT00249158</DOCNO>
	<brief_summary>The purpose study compare effectiveness oral formulation risperidone ( antipsychotic medication ) placebo treat behavioral psychological sign symptom dementia ( BPSSD ) , specifically aggression , delusion , hallucination , patient dementia .</brief_summary>
	<brief_title>A Study Effectiveness Safety Risperidone Treatment Behavioral Disturbances Patients With Dementia</brief_title>
	<detailed_description>Dementia term use collection symptom cause number disease injury affect brain . Individuals dementia loss function cognition ( think , perception , learning , verbal communication , memory , judgment ) , may lead behavioral personality change ( example , agitation , delusion , hallucination ) . Some cause dementia reversible ; however , irreversible dementia cause certain condition , Alzheimer 's disease . Dementia common elderly individual , normal part age . This randomized , double-blind , parallel-group , placebo-controlled study compare effectiveness safety risperidone placebo patient behavioral disturbance associate dementia . The study compose two period : 1-week run-in period patient discontinue antipsychotic drug take placebo twice daily 12-week double-blind period . At end run-in period , patient randomly assign oral solution either risperidone placebo . The start dose risperidone 0.25 mg twice daily increase 0.5 mg twice daily ( 1 mg/day ) . If 1 mg/day show insufficient response , maximum 1 mg twice daily risperidone permit . The patient receive study drug 12-week double-blind period . The primary measure effectiveness change baseline end double-blind treatment Cohen-Mansfield Agitation Inventory ( CMAI ) , questionnaire evaluate agitation . Additional measure efficacy include change baseline end double-blind treatment Behavior Pathology Alzheimer 's Disease Rating Scale ( BEHAVE-AD ) , rating scale use evaluate behavior symptom patient Alzheimer 's disease ; Clinical Global Impressions ( CGI ) , rating system use evaluate overall severity clinical change patient various disease affect brain ; Functional Assessment Staging ( FAST ) , diagnosis tool determine stage dementia ; Mini-Mental State Examination ( MMSE ) , clinical measure use evaluate cognition . Safety evaluation include incidence adverse event ; result clinical laboratory test ( hematology biochemistry ) ; measurement vital sign body weight ; physical examination finding ; Extrapyramidal Symptoms Rating Scale ( ESRS ) , scale use measure effect antipsychotic medication motor function patient . The study hypothesis risperidone effective placebo , measure total aggression score CMAI , treat behavioral disturbance demented patient . Risperidone oral solution ( 1 mg/mL ) . Starting dose 0.25 mg twice daily increase 0.5 mg twice daily ( 1 mg/day ) . If 1 mg/day show insufficient response , maximum 1 mg twice daily risperidone permit . Total treatment duration 12 week .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Dementia Alzheimer 's type behavioral disturbance , vascular dementia behavioral disturbance , mixed dementia , classify DSMIV ( Diagnostic Statistical Manual Mental Diseases , 4th edition ) score &gt; =4 FAST ( Functional Assessment Staging , diagnosis tool determine stage dementia ) score &lt; =23 MMSE ( MiniMental State Examination , clinical measure use evaluate cognition ) BEHAVEAD ( Behavior Pathology Alzheimer 's Disease Rating Scale ) total score &gt; =8 , BEHAVEAD global rating &gt; =1 patient must live nursing home &gt; =1 month . Patients medical neurological condition dementia cognition diminish ( example , severe anemia , severe liver , heart , lung , kidney malfunction , Parkinson 's disease ) diagnosis depression within 6 month study entry , schizophrenia , bipolar affective disorder , schizoaffective disorder history moderate severe tardive dyskinesia , ( condition uncontrollable movement tongue , lip , face , trunk , hand foot see patient receive longterm medication certain type antipsychotic drug ) abnormal clinical laboratory test finding .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>vascular dementia</keyword>
	<keyword>mixed dementia</keyword>
	<keyword>risperidone</keyword>
	<keyword>nursing home</keyword>
</DOC>